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Abstract: A detailed transabdominal and transvaginal ultrasound examination, performed by an 
expert examiner, could render a similar diagnostic performance to computed tomography for 
assessing pelvic/abdominal tumor spread disease in women with epithelial ovarian cancer (EOC). 
This study aimed to describe and assess the feasibility of lung and intercostal upper abdomen 
ultrasonography as pretreatment imaging of EOC metastases of supradiaphragmatic and 
subdiaphragmatic areas. A preoperative ultrasound examination of consecutive patients suspected 
of having EOC was prospectively performed using transvaginal, transabdominal, and intercostal 
lung and upper abdomen ultrasonography. A surgical-pathological examination was the reference 
standard to ultrasonography. Among 77 patients with histologically proven EOC, 
supradiaphragmatic disease was detected in 13 cases: pleural effusions on the right (n = 12) and left 
(n = 8) sides, nodular lesions on diaphragmatic pleura (n = 9), focal lesion in lung parenchyma (n = 
1), and enlarged cardiophrenic lymph nodes (n = 1). Performance (described with area under the 
curve) of combined transabdominal and intercostal upper abdomen ultrasonography for 
subdiaphragmatic areas (n = 77) included the right and left diaphragm peritoneum (0.754 and 0.575 
respectively), spleen hilum (0.924), hepatic hilum (0.701), and liver and spleen parenchyma (0.993 
and 1.0 respectively). It was not possible to evaluate the performance of lung ultrasonography for 
supradiaphragmatic disease because only some patients had this region surgically explored. 
Preoperative lung and intercostal upper abdomen ultrasonography performed in patients with EOC 
can add valuable information for supradiaphragmatic and subdiaphragmatic regions. A reliable 
reference standard to test method performance is an area of future research. A multidisciplinary 
approach to ovarian cancer utilizing lung ultrasonography may assist in clinical decision-making. 
Keywords: lung ultrasonography; pleural cavity; diaphragm; ovarian cancer; diagnostic imaging 
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1. Introduction 
The first-line treatment for primary epithelial ovarian cancer (EOC) is debulking surgery, with 
the goal of removing all macroscopic disease, followed by adjuvant chemotherapy [1]. Before surgery, 
there are two main considerations: first, whether complete cytoreduction is possible; and second, 
estimation of the risk of major complications when complex surgery is planned. Presumed stage and 
surgical complexity, together with patient-related and disease-related variables are important to 
estimate severe postoperative complications after primary debulking surgery [2,3]. For advanced 
EOC where resection to residual disease of 1 cm or less is unlikely or the risk of complication is high, 
neoadjuvant chemotherapy and interval debulking surgery are associated with improved survival 
and reduced perioperative morbidity compared to primary debulking surgery [4]. 
Reliable pre-surgical predictors of resectability would be valuable tools for assigning patients to 
the best management plans [4]. It has been shown that whole-body diffusion-weighted magnetic 
resonance imaging (MRI) assigned more patients with EOC to the correct stage than computed 
tomography (CT) [5]. One-third of patients with serous EOC are diagnosed with stage IV disease [6], 
most commonly because of malignant pleural effusions or parenchymal liver and lung metastases 
[7]. A chest CT is performed as clinically indicated [1]; however, it has 14% sensitivity and 25% 
specificity for pleural status determination, when using video-assisted thoracic surgery as a reference 
[8]. Therefore, more reliable imaging tools for the upper abdomen and pleural space would be 
valuable. 
Ultrasonography performed by an expert examiner might be a useful strategy for staging and 
treatment planning [9–11]. Recently, it was shown that a detailed transabdominal and transvaginal 
ultrasound examination, performed by an expert examiner, could render a similar diagnostic 
performance to CT for assessing pelvic/abdominal tumor spread disease in women with EOC [11]. 
Lung ultrasonography is a recognized imaging modality that can be successfully used in many 
conditions including cancer [12,13]. In a general population of patients with pleural effusions, one 
could suspect malignant effusions based on ultrasonographic findings [14]. Thus, comprehensive 
ultrasound staging with lung ultrasonography could be considered as an alternative imaging 
modality to CT scanning of patients with EOC in specific settings. 
The present study aimed to describe lung and intercostal upper abdomen ultrasonography for 
pre-treatment staging of patients with EOC, demonstrate clinical examples and implications of this 
imaging, test its accuracy, and perform a feasibility study for future research. 
2. Materials and Methods 
A prospective observational study was conducted in a single tertiary cancer center from January 
2017 to March 2019. The Ethical Committee of the Medical Council in Gdańsk, Poland approved the 
study protocol (KB-29/18, 23 Oct 2016), and all women gave informed consent. 
2.1. Patients 
Consecutive patients suspected of having EOC based on a subjective ultrasound assessment and 
scheduled for treatment in our institution, additionally underwent lung and intercostal upper 
abdomen ultrasonography for pre-treatment imaging. Exclusion criteria were final histological 
findings other than EOC, surgery was not performed, and ultrasonography was not performed by an 
expert examiner. 
2.2. Imaging Technique 
All ultrasound imaging was performed by a gynecologist-oncologist experienced in 
ultrasonography. According to our institutional guidelines, ultrasonography was the first and most 
important imaging modality for assessing patients suspected of having EOC. Patient preparations, 
such as enema and fasting, were not necessary, and no contrast agent was used. Abdominal and/or 
chest CT was performed only in selected cases, e.g., those with ambiguous ultrasound findings. 
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2.2.1. Lung and Intercostal upper Abdomen Ultrasonography 
The patient was placed in an upright sitting position, with the thorax exposed to the examiner. 
A Philips HD15® ultrasound instrument (Philips Healthcare, Best, The Netherlands) was used. A 
convex 2.4-5-MHz probe was placed on the back thoracic wall, lateral from the spine. Firstly, the 
kidney was identified. Than the probe was moved up, held vertically and/or horizontally, crossing 
intercostal spaces. The liver was identified on the right side, the spleen on the left side. Next, the 
diaphragm was identified. Later, the probe was moved further up to the scapular bone, and pleural 
spaces and lungs were identified (air-filled lungs did not allow penetration of ultrasound and 
imaging of structures deeper than the pleural line, while pleural effusions and lung consolidation 
“allowed” more detailed examination of the area). After the first scanning, with the probe moved in 
vertical direction on the back thoracic wall, in the next steps the probe was applied to the intercostal 
spaces (probe parallel to ribs) in each lines of the body: vertebral, scapular, posterior axillary, median 
axillary, anterior axillary, midclavicular and sternal. The head was moved along the intercostal spaces 
and stopped in individual lines of the body, and then it was frequently stopped, angled, and tilted 
when spaces were crossed by body lines. We aimed to perform systematic scans of the diaphragm, 
pleural surfaces, lower parts of the pleural space, lungs, and upper abdomen, including the liver on 
the right side and the spleen on the left side. A diagram of the lung and intercostal upper abdomen 
ultrasound examination is presented in Figure 1. 
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Figure 1. An illustration showing the technique of the lung and intercostal upper abdomen ultrasound 
examination (arrows indicate directions of probe application). 
Pathological ultrasound findings that could be detected in a supradiaphragmatic or 
subdiaphragmatic area were described as follows: pleural effusions (increased fluid in the pleural 
space), ascites (fluid between the diaphragm and liver/spleen); nodules (hyperechoic papillary 
projections) on pleural and abdominal surfaces of the diaphragm, bulky tumors (hyperechoic or 
mixed echogenic larger lesions with distinct borders), and plaque infiltration (mixed echogenic 
pathological area without distinct borders). We also searched for the involvement of the spleen/liver 
surface and hilum; parenchymal lesions in the liver, spleen, or lung; and enlarged cardiophrenic 
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lymph nodes. No specific measurements or vascularization assessment was performed, but in a few 
cases, we used color flow Doppler imaging to differentiate small pleural effusions from pleural 
thickening. Videos and still images were recorded and discussed with experienced ultrasound 
operators (AB, NB, and JK). 
2.2.2. Transabdominal and Transvaginal Ultrasonography 
Standard abdominal/pelvis ultrasound scanning was performed with a convex 2.4-5-
MHz/transvaginal 5-9-MHz probe with the patient in the supine and gynecological positions, 
respectively, according to methodology and terminology described elsewhere [9,15]. Liver and 
spleen parenchyma, surface, hepatic and splenic hilum, upper abdomen, diaphragm, and peritoneum 
were scanned with both transabdominal and intercostal upper abdomen ultrasonography. 
All ultrasound data were collected and managed using Research Electronic Data Capture 
(REDCap®, Vanderbilt University, Nashville, TN, USA) [16] before surgery and not changed 
thereafter. The ultrasound examiner was unaware of the results of any additional imaging, if 
performed. 
2.3. Clinical Data 
On the basis of comprehensive ultrasound imaging, we presumed the disease stage (The 
International Federation of Gynecologists and Obstetricians [FIGO] 2014), required surgical 
procedures, and the surgical complexity if primary debulking surgery was attempted. The calculation 
of surgical complexity was based on a scoring system described elsewhere [2] and facilitated with a 
web-based calculator (available online: http://gin-onc-calculators.com/lp.php). In accordance with 
imaging and patients’ clinical data, we suggested management strategies: upfront surgery or 
diagnostic laparoscopy followed by neoadjuvant chemotherapy. 
2.4. Feasibility Study 
In order to perform a feasibility study for future research on the diagnostic performance and 
clinical usefulness of lung and intercostal upper abdomen ultrasonography, we followed guidelines 
described elsewhere [17]. A feasibility studies are used to estimate important parameters that are 
needed to design the main study, e.g., standard deviation of the outcome measure, which is needed 
in some cases to estimate sample size, willingness of participants to be randomized, willingness of 
clinicians to recruit participants, number of eligible patients, characteristics of the proposed outcome 
measure and in some cases feasibility studies might involve designing a suitable outcome measure, 
follow-up rates, adherence/compliance rates, availability of data needed or the usefulness and 
limitations of a particular database, time needed to collect and analyze data [17,18]. 
2.5. Statistical Analysis 
Statistical analysis was performed for ultrasound performance of combined transabdominal and 
intercostal upper abdomen ultrasonography for the subdiaphragmatic region, with a surgical-
pathological examination as the reference standard. Statistical analyses were performed using the 
statistical suite STATISTICA version 12.0 (StatSoft. Inc., Tulsa, OK, USA) and Excel (Microsoft Corp., 
Redmond, WA, USA). To measure the diagnostic performance of ultrasonography, sensitivity, 
specificity, positive and negative predictive values, overall accuracy, the receiver operating 
characteristic curve, and area under the curve (AUC) were calculated (Appendix A). The statistical 
significance level of p < 0.05 was used. 
The sample size for future research on performance of lung ultrasonography was calculated with 
an uncorrected chi-square statistic. Different scenarios were calculated based on available clinical and 
literature data at different statistical threshold parameters. 
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3. Results 
3.1. Patients 
During the study, 87 patients were eligible for inclusion. Ten patients were excluded because of 
the following reasons: non-EOC (n = 6) and surgery not diagnostic for evaluating the upper abdomen 
(n = 4). Ultimately, 77 patients were included. Median patients’ age was 60 years (range, 33–82 years). 
Histological findings indicated high-grade serous carcinoma in 52 (68%) women, endometrioid 
carcinoma in 11 (14%), mucinous in 5 (6%), clear-cell in 3 (4%), mixed in 4 (5%), and non-differentiated 
in 2 (3%). FIGO disease stages were I (n = 6 [8%]), II (n = 4 [5%]), III (n = 54 [70%]), IVa (n = 4 [5%]), 
and IVb (n = 9 [12%]). After excluding patients with FIGO disease stages I and IIA (n = 6) and those 
who underwent diagnostic laparoscopy because of poor performance status or comorbidities (n = 6), 
complete (R0) and optimal (R < 1 cm) cytoreduction was achieved in 40 (61%) and 7 (11%) patients, 
respectively. Median time from the ultrasound examination to surgery was 5 days (range, 1–14). All 
patients expressed their willingness to undergo the additional lung and intercostal upper abdomen 
ultrasound examination, and there were no technical problems associated with this procedure. 
3.2. Imaging 
Supradiaphragmatic disease was detected with lung ultrasonography in 13 cases. Sonographic 
features included pleural effusion on the right (n = 12) and left (n = 8) sides, nodular lesions on the 
diaphragmatic pleura (n = 9) (Figure 2a–d), lesions on the abdominal diaphragmatic surface (Figure 
3a–d), focal lesion in lung parenchyma (n = 1), and enlarged cardiophrenic lymph nodes (n = 1) 
(Figure 4a–d). In most patients, the strong reflection of ultrasound waves from air-filled lungs did 
not allow penetration of ultrasound and imaging of structures deeper than the pleural line. It was not 
possible to test the performance of ultrasonography to evaluate the supradiaphragmatic area because 
not all patients with positive ultrasound findings had this area surgically explored, and those who 
had a negative imaging finding had the pleural cavity surgically explored occasionally (by incidental 
opening during peritoneal stripping of the diaphragm). 
 
Figure 2. Lung ultrasonograms of lesions on the pleural diaphragmatic surface: (a) nodules on the 
right diaphragmatic pleural surface and pleural effusions; (b) pleural nodules and pleural effusions 
on the left side; and (c) (d) Bulky tumors on the right diaphragmatic pleural (and abdominal) surface 
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and pleural effusions. Abbreviations: (*) diaphragm; (A) ascites; (L) liver; (PE) pleural effusions; (S) 
spleen; (T) tumor. Comment: The diaphragm is seen as a “bright line” and indicates the reflection 
between the air-filled lung and adjacent tissues. A normal diaphragm is 3–10 mm thick in the costal 
part and in the crus, respectively. 
 
Figure 3. Intercostal upper abdomen ultrasonograms of lesions on the abdominal diaphragmatic 
surface: (a) bulky tumors between the liver and diaphragm; (b) solid-cystic tumors between the liver 
and diaphragm; (c) tumor on the spleen surface; and (d) plaque lesion on the right posterior 
abdominal surface of the diaphragm and pleural effusions. Abbreviations: (*) diaphragm; (L) liver; 
(PE) pleural effusions; (S) spleen; (T) tumor. 
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Figure 4. Lung ultrasonography and chest computed tomography (CT) of the lower parts of the 
pleural space and lungs: (a) ultrasound presentation of lung consolidation, a sonographic air 
bronchogram with inflammation, and a metastatic parenchymal lung lesion (arrow, FL), pleural 
effusions, and diaphragm thickening; (b) chest CT presentation of lung consolidation in the right and 
left lower lobes; and (c) (d) enlarged cardiophrenic lymph nodes (hyperechoic round lesions) on 
ultrasonography (3c) and chest CT (4d). Abbreviations: (CPLN) cardiophrenic lymph nodes; (DT) 
diaphragm thickening; (FL) focal lesion in the lung; (H) heart; (L) liver; (LA) lung with atelectasis; (T) 
tumor. 
The performance of combined transabdominal and intercostal upper abdomen ultrasonography 
for subdiaphragmatic disease is shown in Table 1, and the AUC was 0.701–1.00, except for the left 
diaphragm and peritoneum (0.575). Specificity was more than 88% for the following evaluated 
regions: right and left diaphragm and peritoneum, hepatic and splenic hilum, and parenchymal 
lesions. Sensitivity values were 90% for the splenic hilum, 60% or less for the diaphragm and hepatic 
hilum, and 100% for liver and spleen parenchymal lesions; however, the latter two were true positive 
in 2 and 1 patients, respectively.
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Table 1. Predictive parameters of preoperative combined transabdominal and intercostal upper abdomen ultrasonography for surgical-pathological findings in the 
subdiaphragmatic area. 
 
Sensitivity  
(95% CI) 
Specificity  
(95% CI) 
PPV 
(95% CI) 
NPV 
(95% CI) 
Overall 
Accuracy 
(95% CI) 
TP 
(n (%)) 
FP 
(n (%)) 
FN 
(n (%)) 
TN 
(n (%)) 
AUC 
(95% CI) 
p-value 
Liver,  
parenchymal lesions 
100.0 
(100.0;100.0) 
98.7 
(96.1;100.0) 
66.7 
(13.3;100.0) 
100.0 
(100.0;100.0) 
98.7 
(96.2;100.0) 
2 
(2.6) 
1 
(1.3) 
0 
(0.0) 
74 
(96.1) 
0.993 
(0.976;1.000) 
<0.0001 
Hepatic hilum 
41.7 
(13.8;69.6) 
98.5 
(95.5;100.0) 
83.3 
(53.5;100.0) 
90.1 
(83.2;97.1) 
89.6 
(82.8;96.4) 
5 
(6.5) 
1 
(1.3) 
7 
(9.1) 
64 
(83.1) 
0.701 
(0.509;0.892) 
0.0403 
Spleen,  
parenchymal lesions 
100.0 
(100.0;100.0) 
100.0 
(100.0;100.0) 
100.0 
(100.0;100.0) 
100.0 
(100.0;100.0) 
100.0 
(100.0;100.0) 
1 
(1.3) 
0 
(0.0) 
0 
(0.0) 
76 
(98.7) 
1.00 
(1.00;1.00) 
<0.0001 
Spleen hilum 
90.0 
(76.9;100.0) 
94.7 
(88.9;100.0) 
85.7 
(70.8;100.0) 
96.4 
(91.6;100.0) 
93.5 
(88.0;99.0) 
18 
(23.4) 
3 
(3.9) 
2 
(2.6) 
54 
(70.1) 
0.924 
(0.840;1.000) 
<0.0001 
Diaphragm, right side 
62.0 
(48.6;75.5) 
88.9 
(77.0;100.0) 
91.2 
(81.6;100.0) 
55.8 
(41.0;70.7) 
71.4 
(61.3;81.5) 
31 
(40.3) 
3 
(3.9) 
19 
(24.7) 
24 
(31.2) 
0.754 
(0.644;0.865) 
<0.0001 
Diaphragm, left side 
16.7 
(0.0;33.9) 
98.3 
(95.0;100.0) 
75.0 
(32.6;100.0) 
79.5 
(70.2;88.7) 
79.2 
(70.2;88.3) 
3 
(3.9) 
1 
(1.3) 
15 
(19.5) 
58 
(75.3) 
0.575 
(0.414;0.736) 
0.3629 
Abbreviations: AUC, area under the receiver operating characteristic curve; FN, false negative; FP, false positive; NPV, negative predictive value; PPV, positive 
predictive value; TN, true negative; TP true positive.
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3.3. Clinical Implementation 
Clinical examples of the implementation of lung and intercostal upper abdomen 
ultrasonography in pretreatment imaging are presented in Appendix B, and examples of 
images/loops with the corresponding surgical or CT presentations are shown in supplementary video 
materials (Video S1–Video S9). 
3.4. Feasibility Study 
In order to obtain meaningful results, the sample size for future research to evaluate the accuracy 
of lung ultrasonography was estimated at 160–240 cases, under the following conditions: type I error 
probability of 0.05, test power of 80%, and possible positive detection in 20–30% of consecutive 
patients with EOC. 
4. Discussion 
We described the use of lung and intercostal upper abdomen ultrasonography as a part of 
pretreatment imaging staging of patients with EOC. Supradiaphragmatic disease can be detected 
with lung ultrasonography, with pleural effusions being the easiest sonographic sign, and the 
“contrast” that enables detection of other larger lesions. Accuracy of a combined transabdominal and 
intercostal upper abdomen ultrasound examination in the subdiaphragmatic region was fair to 
excellent, except for the left abdominal diaphragm. Lung and intercostal upper abdomen 
ultrasonography enabled the presumption of stage IV disease, planning additional surgical 
procedures if primary cytoreduction was attempted, or modifying the initial management (upfront 
surgery or neoadjuvant chemotherapy). The feasibility study pointed to important obstacles that 
need to be addressed when planning a study to test the diagnostic accuracy and clinical usefulness 
of lung ultrasonography. 
A detailed transabdominal/transvaginal examination performed by an expert examiner may 
offer similar diagnostic performance to CT for assessing abdominal tumor spread in women with 
EOC [11]. Overall sensitivities of ultrasonography and CT were 70.3% and 60.1%, respectively, and 
specificities were 97.8% and 93.7%, respectively. Compared to CT, ultrasonography had a slightly 
better sensitivity for pelvic regions and the omentum and worse sensitivity for assessing the small 
bowel; however, it was identical for assessing the root of the mesentery, mesogastrium, hepatic 
hilum, liver and spleen parenchyma, and retroperitoneal space [11]. Of note, after the initial exclusion 
of patients with extra-abdominal disease in this study, there were still 6 patients with stage IVa 
disease and 3 with stage IVb disease (probably parenchymal liver metastases). Ultrasonography 
underestimated 7 of 9 patients with stage IV (CT did not miss any) [11]. Perhaps physicians relying 
on lung and intercostal upper abdomen ultrasonography would assign more patients with pleural 
effusions and liver lesion to stage IV disease. 
In another study comparing the diagnostic accuracy of transabdominal/transvaginal 
ultrasonography, CT, and whole-body diffusion-weighted MRI in EOC staging, ultrasonography 
showed the best results in disease detection in the pelvis and omentum; all three methods showed 
comparable results in the detection of the bowel surface and liver involvement, whereas 
ultrasonography had the lowest accuracy in the assessment of the diaphragm [19]. The sensitivity, 
specificity, and AUC of ultrasonography were 30.8%, 98.9%, and 0.648, respectively, for the detection 
of diaphragm carcinomatosis [10]. We showed that with combined transabdominal and intercostal 
upper abdomen ultrasonography of the right abdominal diaphragm, the sensitivity and AUC could 
be improved to 62.0% and 0.754, respectively. Nevertheless, still the rates of false negative were 
relatively high in the right and left side of diaphragm region (24.7% and 19.5%, respectively). This 
could be attributable to miliary peritoneal carcinomatosis—a form of a low volume disease, fine 
nodules that do not grow out significantly of the peritoneal surface (see Video S9), thus are difficult 
to be detected with ultrasonography. Also, performance of ultrasonography was worse on the left 
diaphragm as compared to the right side (AUC 0.575 vs 0.754). This could be attributable to the fact, 
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that there is an air-filled stomach on the left side, which may cause reflections of ultrasound waves. 
Moreover, the area between parenchymal organ and diaphragm on both sides is important in terms 
of imaging performance. The proximity and large area between the liver and diaphragm “enables” 
detection of peritoneal nodules that (if present) “disrupt” this otherwise smooth border. The spleen 
is small as compared to the liver, so the area between the diaphragm and parenchymal organ is 
smaller on the left side than on the right side. These could explain differences between left and right 
diaphragm imaging with ultrasound. From the surgical point of view, failure to detect low volume 
disease on the diaphragm peritoneum pre-operatively is not a major problem, because diaphragm 
peritonectomy with miliary carcinomatosis is relatively simple and quick procedure. 
Ultrasonography of the pleurae and lungs, including the diaphragm, has been extensively 
described [12,13]. Detection and estimation of the pleural effusion volume using ultrasonography is 
reproducible and independent of the operator [12]. In the presence of pleural effusions, an acoustic 
window allows physicians to visualize the diaphragm and pleural cavity, thus a more detailed 
examination may reveal additional lesions. In the absence of free fluid, the phenomenon of a strong 
reflection of ultrasound waves from air-filled lungs does not allow penetration of ultrasound and 
imaging of structures deeper than the pleural line. Lung ultrasonography is a good diagnostic 
strategy to use for a transthoracic biopsy in the diagnosis of subpleural masses that are suspicious of 
malignancy [13], or to perform safe ultrasound-guided thoracocentesis [12]. For patients with 
advanced EOC, in whom pleural effusions or metastatic disease is suspected, video-assisted 
thoracoscopic surgery is considered a safe and accurate method for diagnosing metastases in the 
pleural cavity [8,20], and it can be planned immediately after lung ultrasonography. 
Interestingly, there is ongoing research on the ultrasound evaluation of mediastinal lymph 
nodes with the use of transthoracic [21] and endobronchial and transesophageal ultrasonography 
[22]. Many other conditions, such as pneumothorax, atelectasis, pneumonia, pulmonary embolism, 
and cardiogenic pulmonary edema, can be diagnosed and evaluated using ultrasonography of the 
chest [13]. Patients with advanced EOC may suffer all aforementioned conditions. 
Lung ultrasonography can save time and money, is readily available, and has no associated 
complications, side effects, or radiation exposure [12]. The examination can be performed early at the 
time of counselling and indicate the need for additional pretreatment work-up or serve as a single 
imaging modality. In contrast, performance of CT/MRI requires patient preparation, contrast intake, 
scheduling, and transportation to the CT/MRI departments. The estimated prices of abdominal/pelvic 
and pleural ultrasonography were 20% and 12% of the price of abdominal/pelvic and chest CT or 
MRI, respectively, in our institution. 
The limitations of this study include its relatively small sample size, ultrasonography was 
performed by a single examiner, and it was not possible to systematically test positive and negative 
findings from lung ultrasonography with the surgical-pathological reference. 
As for the feasibility of future research in the field of lung ultrasonography, some obstacles need 
to be addressed. Most studies analyzing the diagnostic accuracy of the imaging modality consider 
the surgical-pathological examination as the reference index. In the case of positive lung ultrasound 
findings in the supradiaphragmatic area, video-assisted thoracoscopic surgery seems the most 
appropriate procedure to serve as the reference standard, but it would test only true and false positive 
ultrasound findings. However, it would be difficult and unethical to submit patients for thoracoscopy 
in cases of negative lung ultrasound findings. Thus, the study design should rather include chest CT 
or MRI as the reference test for this area. Nevertheless, one must be aware that this solution would 
also lead to bias, as these imaging techniques are not as accurate as the surgical-pathological 
examination. In our setting, two patients had pleural nodular lesions detected with lung 
ultrasonography that were not detected by CT. Another issue for future study is that 
transabdominal/transvaginal findings should be recorded first, and lung and intercostal upper 
abdomen ultrasound diagnoses should be added separately in the second round of the examination—
this procedure would enable testing of whether lung and intercostal upper abdomen 
ultrasonography adds value to transabdominal/transvaginal ultrasound staging and provides a 
clinical advantage. Moreover, intercostal ultrasonography is an additional procedure performed in a 
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different patient position, and it requires extra time; thus, some clinicians might not be willing to 
recruit patients for such procedure. To test the possible clinical advantage/impact of lung and 
intercostal upper abdomen ultrasonography, a larger prospective trial should be conducted, and the 
following data should be collected: proportions of patients undergoing primary debulking surgery 
versus neoadjuvant chemotherapy and data about complete cytoreduction, adjuvant chemotherapy, 
disease-free survival, and overall survival. 
5. Conclusions 
Preoperative lung and intercostal upper abdomen ultrasonography performed in patients with 
EOC can add valuable information for disease spread in supradiaphragmatic and subdiaphragmatic 
regions, enable presumption of the disease stage and surgical complexity if upfront surgery is 
planned, or guide initial management. Performance of lung and intercostal upper abdomen 
ultrasonography is relatively easy (although it needs specific training), cost-effective, and does not 
require any special preparation. Therefore, it could be considered as additional or an independent 
imaging modality, especially in low resource settings. The accuracy of the method should be tested 
on a larger population, with the possible reference standard being thoracoscopy or eventually 
abdominal/chest MRI. A future area of investigation in the field should focus on improvement of the 
lung ultrasound technique by multidisciplinary interactions and training that involves scanning of 
the whole pleural cavity, lungs, and mediastinum, and consideration of contrast enhancement. 
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Abbreviations 
CT computed tomography 
DLSK diagnostic laparoscopy 
ICAUS intercostal upper abdomen ultrasonography 
IDS interval debulking surgery 
LUS lung ultrasonography 
MRI magnetic resonance imaging 
NACT neoadjuvant chemotherapy 
OC ovarian cancer 
PDS primary debulking surgery 
TAS transabdominal ultrasonography 
TVS transvaginal ultrasonography 
Appendix A 
More detailed description of statistical analysis. 
Sensitivity is a ratio of true positive cases to all real positive cases: TP/(TP+FN), where TP – true 
positive, FN – false negative. Specificity determines the share of true negatives cases to all real 
negative cases: TN/(FP+TN), where TN – true negative, FP – false positive. The positive predicted 
values (PPV) and the negative predicted values (NPV) are the two other indices that are useful in 
clinical practice when test results are available for the clinicians. The PPV is defined as the probability 
of disease for positive test results and the NPV is also defined the probability of being healthy for 
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negative test results. Overall accuracy of a test is its ability to differentiate the patient and healthy 
cases correctly: (TP+TN)/(TP+TN+FP+FN). 
Determination of the receiver operating characteristic (ROC) curve and the area under the curve 
(AUC) was related to calculation of sensitivity and specificity measures. ROC curve is a set of points: 
x,y, where x =1 − specificity, y = sensitivity and for a particular decision threshold value u sensitivity 
and specificity is determined. The AUC is an effective and combined measure of sensitivity and 
specificity that describes the inherent validity of diagnostic tests (from 0 to 1). 
Appendix B 
Clinical examples of the implementation of lung and intercostal upper abdomen 
ultrasonography in pretreatment imaging. 
Case 1: With LUS, we detected hyperechoic nodules on the right diaphragmatic pleural surface 
and a echogenic pleural effusions with sedimentation symptom (Figure 2a). LUS enabled 
performance of safe thoracocentesis. Due to patient’s poor performance status, a DLSK was 
performed before referring for NACT. 
Case 2: With LUS, we detected pleural nodules and anechoic pleural effusions on the left side 
(Figure 2b and Video S1). PDS was attempted with a plan to explore left pleural cavity but the surgery 
was aborted due to infiltration of the hepatic hilum (not previously suspected). 
Case 3: With LUS/ICAUS, we detected echogenic pleural effusions and bulky hyperechoic tumor 
lesions with regular smooth borders, in the right pleural cavity (Figure 2c, Figure 2d, and Video S2) 
and on the abdominal side of the diaphragm, which pressed on the liver (Figure 3a and Video S2). 
The patient was referred to upfront surgery, because she presented symptoms of low bowel 
obstruction. A radical oophorectomy resolved the obstruction; cytoreduction was continued in the 
right upper abdomen, and it involved a full-thickness diaphragm resection that resulted in complete 
debulking. LUS/ICAUS performed before surgery enabled planning the resection extent and 
appropriate team and time slot in operating room. 
Case 4: With LUS/ICAUS, we detected solid-cystic tumors between the liver and diaphragm, 
close to the mid-line (Figure 3b and Video S3). This patient presented low bowel obstruction 
symptoms for which she underwent laparotomy with radical oophorectomy and colostomy. In the 
upper abdomen a fixed, confluent infiltration spread was detected on a large surface of the right 
diaphragm, located close to the mid-line. Having additional information from the LUS/ICAUS (tumor 
proximity to right atrium of the heart, and thus potential involvement of hepatic veins and vena cava 
inferior) and CT imaging (tumor in direct contact with right hepatic vein), the disease was considered 
unresectable. 
Case 5: With ICAUS, we detected small lesions, including hyperechoic nodules or plaque 
thickening, on the diaphragmatic surface of the spleen (part of the omental cake) (Figure 3c and Video 
S4). We also detected a mixed echogenic plaque lesion on the right posterior abdominal surface of 
the diaphragm (Figure 3d and Video S4). ICAUS added important information about disease extent 
and required surgical complexity if PDS was planned. Due to her age and poor performance status 
we performed DLSK and the patient was referred for NACT. 
Case 6: With ICAUS, we detected hyperechoic, plaque lesion of the diaphragm, pressing on liver 
surface and hyperechoic, nodular lesions in the spleen hilum (Video S5, Video S6). The case was 
submitted for PDS with a planned diaphragm peritoneum stripping, possible superficial liver 
resections and splenectomy. All procedures deemed necessary. 
Case 7: With combination of TAS/ICAUS, we detected the involvement of the ligamentum teres 
of the liver and the hepatic hilum (hyper- and hypoechoic lesions). In this case, complete 
cytoreduction was not possible (Video S7). 
Case 8: With LUS, we visualized anechoic pleural effusions, diaphragm thickening and lung 
consolidation with dynamic air bronchogram (pneumonia); inside a consolidation a round and 
anechoic focal lesion was detected – a metastasis. A thorax CT only showed heterogeneous 
consolidation/atelectasis in the right and left lower lobes (Figure 4a, Figure 4b and Video S8). Due to 
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patient’s age and performance status she was referred for NACT after a DLSK. LUS added important 
information about the disease extent. 
Also, enlarged cardiophrenic lymph nodes (hyperechoic round lesions) could be detected with 
LUS (Case 4) and confirmed with CT (Figure 4c, Figure 4d). 
Some lesions could not be detected with LUS/ICAUS, for example, a fine, miliary (<3mm) 
diaphragm peritoneal carcinomatosis (Video S9). 
Clinical examples are summarized in the Table A1. 
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Table A1. Patients’ age, performance status, main ultrasound findings, and impact of lung ultrasound (LUS) and intercostal upper abdomen ultrasound (ICAUS) on staging 
and surgical complexity. 
No. Age PS TAS/TVS LUS/ICAUS CT 
Upstaging 
(IIIC → IV) 
with 
LUS/ICAUS 
added to 
TAS/TVS? 
 
Additional 
Procedures 
Planned after 
LUS/ICAUS? 
LUS/ICAUS 
Added to 
TAS/TVS 
Changed 
Predicted 
Surgical 
Complexity [2]? 
VATS 
Necessary? 
Figure 
VS 
Management 
/Comments 
1 71 3 
ascites, massive 
pelvic involvement, 
omental involvement, 
spleen involvement 
pleural diaphragm 
involvement*, 
pleural effusions 
ascites, carcinomatosis, 
massive pelvic 
involvement, omental 
involvement, pleural 
effusions, spleen 
involvement 
Yes Yes 
NoScore: 9 → 11 
High → High 
 
Could 
replace 
DLSK 
2a 
DLSK, HGSOC, 
NACT 
2 62 1 
ascites, 
carcinomatosis, 
omental involvement, 
spleen involvement 
abdominal 
diaphragm 
involvement**, 
pleural effusions, 
ligamentum teres of 
the liver 
involvement 
- Yes Yes 
YesScore: 6 → 8 
Intermediate → 
High 
Could 
precede 
PDS 
2b, 
VS1 
PDS attempt. 
HGSOC, R>1cm 
3 53 3 
ascites, massive 
pelvic involvement, 
omental involvement 
abdominal 
diaphragm 
involvement**, 
pleural diaphragm 
involvement*, 
pleural effusions 
- Yes Yes 
YesScore: 6 → 8 
Intermediate → 
High 
No 
2c, 2d, 
3a,  
VS2 
PDS, mucinous 
G3. R = 
microscopic 
4 48 3 
ascites, 
carcinomatosis, 
massive pelvic 
involvement, omental 
involvement 
abdominal 
diaphragm 
involvement**, 
other*, pleural 
effusions 
ascites, abdominal 
diaphragm 
involvement,  
carcinomatosis,  
massive pelvic 
involvement,  other*, 
omental involvement, 
pleural effusions 
Yes Yes 
YesScore: 7 → 9 
Intermediate → 
High 
No 
3b, 4c, 
4d,  
VS3 
PDS attempt 
because of low 
bowel obstruction 
symptoms. 
HGSOC, R>1cm.  
*suspected 
enlarged 
cardiophrenic 
lymph nodes 
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5 79 3 
ascites, 
carcinomatosis, 
omental involvement 
abdominal 
diaphragm 
involvement**, 
pleural effusions, 
spleen involvement 
- Yes Yes 
Yes Score: 4 → 8 
Intermediate → 
High 
 
No 
3c, 3d,  
VS4 
DLSK, HGSOC, 
NACT 
6 
 60 1 
massive pelvic 
involvement, omental 
involvement 
abdominal 
diaphragm 
involvement**,  
spleen involvement, 
- Yes Yes 
YesScore: 6 → 10 
Intermediate → 
High 
 
No 
VS5, 
VS6 
PDS, HGSOC, R 
microscopic 
7 69 2 
ascites, bowel 
mesentery 
involvement, 
carcinomatosis, 
massive pelvic 
involvement, omental 
involvement 
 
ligamentum teres of 
the liver 
involvement 
- Yes Yes 
NoScore: 8 → 10 
High → High 
 
No VS7 
DLSK, HGSOC, 
NACT. 
8 74 3 
ascites, 
carcinomatosis, 
massive pelvic 
involvement, omental 
involvement  
pleural diaphragm 
involvement *, lung 
parenchymal 
pathology,  pleural 
effusions 
ascites, carcinomatosis,  
massive pelvic 
involvement, omental 
involvement,  pleural 
effusions, other 
Yes Yes 
YesScore: 7 → 9 
Intermediate → 
High 
No 
4a, 4b, 
VS8 
DLSK, HGSOC. 
NACT. 
Note: (*) Pleural diaphragm involvement – nodes or plaque infiltration detected on the pleural side of diaphragm; (**) Abdominal diaphragm involvement – nodes or plaque infiltration detected on the 
abdominal side of diaphragm. Abbreviations: (CT) Computed tomography; (DLSK) Diagnostic laparoscopy; (HGSOC) High grade serous ovarian cancer; (ICAUS) intercostal upper abdomen ultrasound; 
(LUS) lung ultrasound; (NACT) Neoadjuvant chemotherapy; (PDS) Primary debulking surgery; (PS) Eastern Cooperative Oncology Group performance status; (TAS) Transabdominal sonography; (TVS) 
Transvaginal sonography; (VATS) Video assisted thoracoscopic surgery; (VS) Video S (Supplementary)
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